In:
Cancer Medicine, Wiley, Vol. 7, No. 9 ( 2018-09), p. 4447-4455
Abstract:
Although the prognosis of core‐binding factor ( CBF ) acute myeloid leukemia ( AML ) is better than other subtypes of AML , 30% of patients still relapse and may require allogeneic hematopoietic cell transplantation (allo HCT ). However, there is no validated widely accepted scoring system to predict patient subsets with higher risk of relapse. Methods Eleven centers in the US and Europe evaluated 247 patients with t(8;21)(q22;q22). Results Complete remission ( CR ) rate was high (92.7%), yet relapse occurred in 27.1% of patients. A total of 24.7% of patients received allo HCT . The median disease‐free ( DFS ) and overall ( OS ) survival were 20.8 and 31.2 months, respectively. Age, KIT D816V mutated (11.3%) or nontested (36.4%) compared with KIT D816V wild type (52.5%), high white blood cell counts ( WBC ), and pseudodiploidy compared with hyper‐ or hypodiploidy were included in a scoring system (named I‐ CBF it). DFS rate at 2 years was 76% for patients with a low‐risk I‐ CBF it score compared with 36% for those with a high‐risk I‐ CBF it score ( P 〈 0.0001). Low‐ vs high‐risk OS at 2 years was 89% vs 51% ( P 〈 0.0001). Conclusions I‐ CBF it composed of readily available risk factors can be useful to tailor the therapy of patients, especially for whom allo HCT is not need in CR 1 (ie, patients with a low‐risk I‐ CBF it score).
Type of Medium:
Online Resource
ISSN:
2045-7634
,
2045-7634
DOI:
10.1002/cam4.2018.7.issue-9
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2659751-2